Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Calocurb is a private New Zealand consumer health and nutraceutical company commercializing a plant-based appetite control supplement under the Calocurb brand. Its core product is a prescription-free capsule containing Amarasate, a patented bitter hops extract developed in New Zealand and marketed as a natural activator of satiety-related gut hormone pathways including GLP-1. The company focuses on weight-management support, hunger reduction, and craving control through direct-to-consumer e-commerce and practitioner channels rather than traditional prescription therapeutics. Calocurb appears to operate as a commercial-stage wellness and health-supplement business rather than a clinical-stage biotech drug developer. The business is active, venture-backed, and sells primarily through its own branded online storefronts in multiple geographies.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Calocurb.